Want to join the conversation?
Robert Koort of Goldman Sachs asks about $MON's glyphosate pricing levels and expectations. COO Brett Begemann said $MON believes it has reached the bottom range of glyphosate pricing and there is nothing in the near-term that will shift this and move it in a different direction. $MON is comfortable in its cost position.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.